Q2 2023 · 13F-HR
BML Capital Management, LLCholdings as filed
Filed 2023-07-24 · accession 0001754960-23-000204
$111.2M
Reported value
31
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78468R663 | BIL | SPDR SER TR | $18.4M | 16.5% | 200,000 | Common | NONE |
| 46436E718 | SGOV | ISHARES TR | $18.1M | 16.3% | 180,000 | Common | NONE |
| 23284P103 | — | CYTEIR THERAPEUTICS INC | $8.4M | 7.60% | 3,250,000 | Common | NONE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $8.4M | 7.52% | 2,236,239 | Common | NONE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $8.2M | 7.38% | 5,157,179 | Common | NONE |
| 69945Q105 | — | PARDES BIOSCIENCES INC | $6.9M | 6.17% | 3,791,633 | Common | NONE |
| 87410C104 | — | TALARIS THERAPEUTICS INC | $6.1M | 5.47% | 2,000,000 | Common | NONE |
| 04746L104 | — | ATHIRA PHARMA INC | $5.5M | 4.95% | 1,864,907 | Common | NONE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $4.4M | 3.99% | 1,583,170 | Common | NONE |
| 002896207 | ANF | ABERCROMBIE & FITCH CO | $4.4M | 3.98% | 117,500 | Common | NONE |
| 046484309 | ASTC | ASTROTECH CORP | $3.1M | 2.81% | 220,410 | Common | NONE |
| 68403P203 | ORMP | ORAMED PHARMACEUTICALS INC | $3.0M | 2.74% | 850,000 | Common | NONE |
| 22053A107 | — | QUINCE THERAPEUTICS INC | $2.1M | 1.91% | 1,411,839 | Common | NONE |
| 702712100 | — | PASSAGE BIO INC | $1.9M | 1.74% | 2,058,767 | Common | NONE |
| 34962G109 | TOCAEUR | FORTE BIOSCIENCES INC | $1.8M | 1.62% | 1,735,075 | Common | NONE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $1.5M | 1.36% | 74,232 | Common | NONE |
| 00211Y506 | ABIOEUR | ARCA BIOPHARMA INC | $1.4M | 1.29% | 706,930 | Common | NONE |
| 886885102 | TLYS | TILLYS INC | $1.3M | 1.20% | 190,518 | Common | NONE |
| 128058302 | LSTA | LISATA THERAPEUTICS INC | $902,204 | 0.81% | 243,839 | Common | NONE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $865,500 | 0.78% | 150,000 | Common | NONE |
| 86889P109 | — | SURROZEN INC | $802,496 | 0.72% | 1,459,084 | Common | NONE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $776,625 | 0.70% | 272,500 | Common | NONE |
| 76129W105 | RVP | RETRACTABLE TECHNOLOGIES INC | $768,861 | 0.69% | 668,575 | Common | NONE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $551,637 | 0.50% | 306,465 | Common | NONE |
| 38870X104 | GRPH | GRAPHITE BIO INC | $395,957 | 0.36% | 152,291 | Common | NONE |
| 38942Q202 | CALC | CALCIMEDICA INC | $356,012 | 0.32% | 88,781 | Common | NONE |
| 05455M100 | — | AVROBIO INC | $243,489 | 0.22% | 256,277 | Common | NONE |
| 55279B301 | LITS | MEI PHARMA INC | $151,116 | 0.14% | 22,966 | Common | NONE |
| 00534A102 | IVVD | INVIVYD INC | $141,431 | 0.13% | 134,696 | Common | NONE |
| 75082Q105 | — | RAIN ONCOLOGY INC | $87,511 | 0.08% | 72,926 | Common | NONE |
| 64049K104 | — | NEOLEUKIN THERAPEUTICS INC | $19,712 | 0.02% | 23,749 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.